| 4425-5 |
Sotalol |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Sotalol [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4425-5 |
|
|
|
|
Observation |
|
|
|
0 |
Sotalol Dose |
|
|
|
Y |
|
Beta-cardone; Betapace; Betudes; Dose med or substance; DRUG DOSES; Point in time; QNT; Quan; Quant; Quantitative; Random; Solalex; Sotacor |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 44250-9 |
Little interest or pleasure in doing things in last 2W |
Find |
^Patient |
2W |
Ord |
|
|
ACTIVE |
Little interest or pleasure in doing things in last 2 weeks |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.PHQ |
|
44250-9 |
|
|
|
|
Observation |
|
|
|
0 |
|
|
|
|
N |
|
14 days; 2 weeks; Finding; Findings; Mental health; MentalHealth; Ordinal; Past; Patient Health Questionnaire; Psych; Psychiatry; Ql; Qual; Qualitative; Screen; Survey; SURVEY.PHQ |
2.72 |
2.17 |
|
|
|
|
|
|
|
|
|
|
Release 2.72: AnswerListId: Updated to a more general list without associated codes; METHOD_TYP: Removed Method because this concept is not specific to PHQ; SURVEY_QUEST_TEXT: Moved from the individual term level to the instance of this term in the panel; ANSWER_LIST_TYPE: Updated from Normative to Example for increased usability; EXTERNAL_COPYRIGHT_LINK: Removed copyright because this concept is not specific to PHQ9; SURVEY_QUEST_SRC: Moved from the individual term level to the instance of this term in the panel.; |
0 |
| 44251-7 |
Poor appetite or overeating in last 2W |
Find |
^Patient |
2W |
Ord |
Reported.PHQ |
|
ACTIVE |
Poor appetite or overeating in last 2 weeks [Reported.PHQ] |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
SURVEY.PHQ |
|
44251-7 |
|
Reported.PHQ |
|
|
Observation |
|
|
|
0 |
|
|
PHQ-9.5 |
Poor appetite or overeating |
N |
|
14 days; 2 weeks; Finding; Findings; Mental health; MentalHealth; Ordinal; Past; Patient Health Questionnaire; Psych; Psychiatry; Ql; Qual; Qualitative; Screen; Survey; SURVEY.PHQ |
2.54 |
2.17 |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
|
|
0 |
| 44252-5 |
Trouble concentrating on things, such as reading the newspaper or watching television in last 2W |
Find |
^Patient |
2W |
Ord |
Reported.PHQ |
|
ACTIVE |
Trouble concentrating on things, such as reading the newspaper or watching television in last 2 weeks [Reported.PHQ] |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
SURVEY.PHQ |
|
44252-5 |
|
Reported.PHQ |
|
|
Observation |
|
|
|
0 |
|
|
PHQ-9.7 |
Trouble concentrating on things, such as reading the newspaper or watching television |
N |
|
14 days; 2 weeks; Arterial Stenosis; Finding; Findings; Mental health; MentalHealth; Ordinal; Past; Patient Health Questionnaire; Psych; Psychiatry; Ql; Qual; Qualitative; Screen; Survey; SURVEY.PHQ |
2.54 |
2.17 |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
|
|
0 |
| 44253-3 |
Moving or speaking so slowly that other people could have noticed. Or the opposite - being so fidgety or restless that you have been moving around a lot more than usual in last 2W |
Find |
^Patient |
2W |
Ord |
Reported.PHQ |
|
ACTIVE |
Moving or speaking so slowly that other people could have noticed. Or the opposite - being so fidgety or restless that you have been moving around a lot more than usual in last 2 weeks [Reported.PHQ] |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
SURVEY.PHQ |
|
44253-3 |
|
Reported.PHQ |
|
|
Observation |
|
|
|
0 |
|
|
PHQ-9.8 |
Moving or speaking so slowly that other people could have noticed. Or the opposite ââ?¬â?? being so fidgety or restless that you were moving around a lot more than usual |
N |
|
14 days; 2 weeks; Finding; Findings; Mental health; MentalHealth; Ordinal; Othr; Past; Patient Health Questionnaire; Psych; Psychiatry; Ql; Qual; Qualitative; Screen; Survey; SURVEY.PHQ |
2.78 |
2.17 |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
|
|
0 |
| 44254-1 |
Feeling tired or having little energy in last 2W |
Find |
^Patient |
2W |
Ord |
Reported.PHQ |
|
ACTIVE |
Feeling tired or having little energy in last 2 weeks [Reported.PHQ] |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
SURVEY.PHQ |
|
44254-1 |
|
Reported.PHQ |
|
|
Observation |
|
|
|
0 |
|
|
PHQ-9.4 |
Feeling tired or having little energy |
N |
|
14 days; 2 weeks; Finding; Findings; Mental health; MentalHealth; Ordinal; Past; Patient Health Questionnaire; Psych; Psychiatry; Ql; Qual; Qualitative; Screen; Survey; SURVEY.PHQ |
2.54 |
2.17 |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
|
|
0 |
| 44255-8 |
Feeling down, depressed, or hopeless in last 2W |
Find |
^Patient |
2W |
Ord |
|
|
ACTIVE |
Feeling down, depressed, or hopeless in last 2 weeks |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SURVEY.PHQ |
|
44255-8 |
|
|
|
|
Observation |
|
|
|
0 |
|
|
|
|
N |
|
14 days; 2 weeks; Finding; Findings; Mental health; MentalHealth; Ordinal; Past; Patient Health Questionnaire; Psych; Psychiatry; Ql; Qual; Qualitative; Screen; Survey; SURVEY.PHQ |
2.72 |
2.17 |
|
|
|
|
|
|
|
|
|
|
Release 2.72: METHOD_TYP: Removed Method because this concept is not specific to PHQ; EXTERNAL_COPYRIGHT_LINK: Removed copyright because this concept is not specific to PHQ; SURVEY_QUEST_SRC: Moved from the individual term level to the instance of this term in the panel.; SURVEY_QUEST_TEXT: Moved from the individual term level to the instance of this term in the panel.; AnswerListId: Updated to a more general list without associated codes; ANSWER_LIST_TYPE: Updated from Normative to Example for increased usability; |
0 |
| 44256-6 |
Perceived difficulty in last 2W |
Find |
^Patient |
2W |
Ord |
Reported.PHQ |
|
ACTIVE |
Perceived difficulty in last 2 weeks [Reported.PHQ] |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
SURVEY.PHQ |
|
44256-6 |
|
Reported.PHQ |
|
|
|
|
|
|
0 |
|
|
PHQ-9.10 |
If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people? |
N |
|
14 days; 2 weeks; Finding; Findings; Mental health; MentalHealth; Ordinal; Past; Patient Health Questionnaire; Psych; Psychiatry; Ql; Qual; Qualitative; Screen; Survey; SURVEY.PHQ |
2.54 |
2.17 |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
|
|
0 |
| 44257-4 |
Patient health questionnaire 9 item |
- |
^Patient |
Pt |
- |
Reported.PHQ |
|
DEPRECATED |
Deprecated Patient Health Questionnaire 9 item (PHQ-9) [Reported] |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
SURVEY.PHQ |
|
44257-4 |
|
Reported.PHQ |
|
|
Observation |
|
|
|
0 |
|
|
PHQ-9.0 |
Over the last 2 weeks, how often have you been bothered by any of the following problems? |
N |
|
Patient Health Questionnaire; PHQ; PHQ 9; PHQ9; PHQ-9; Point in time; Random; Survey; SURVEY.PHQ |
2.7 |
2.17 |
|
Panel |
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 44258-2 |
Feeling bad about yourself - or that you are a failure or have let yourself or your family down in last 2W |
Find |
^Patient |
2W |
Ord |
Reported.PHQ |
|
ACTIVE |
Feeling bad about yourself - or that you are a failure or have let yourself or your family down in last 2 weeks [Reported.PHQ] |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
SURVEY.PHQ |
|
44258-2 |
|
Reported.PHQ |
|
|
Observation |
|
|
|
0 |
|
|
PHQ-9.6 |
Feeling bad about yourself-or that you are a failure or have let yourself or your family down |
N |
|
14 days; 2 weeks; Finding; Findings; Mental health; MentalHealth; Ordinal; Past; Patient Health Questionnaire; Psych; Psychiatry; Ql; Qual; Qualitative; Screen; Survey; SURVEY.PHQ |
2.54 |
2.17 |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
|
|
0 |
| 44259-0 |
Trouble falling or staying asleep, or sleeping too much in last 2W |
Find |
^Patient |
2W |
Ord |
Reported.PHQ |
|
ACTIVE |
Trouble falling or staying asleep, or sleeping too much in last 2 weeks [Reported.PHQ] |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
SURVEY.PHQ |
|
44259-0 |
|
Reported.PHQ |
|
|
|
|
|
|
0 |
|
|
|
Trouble falling or staying asleep, or sleeping too much |
N |
|
14 days; 2 weeks; Finding; Findings; Mental health; MentalHealth; Ordinal; Past; Patient Health Questionnaire; Psych; Psychiatry; Ql; Qual; Qualitative; Screen; Survey; SURVEY.PHQ |
2.54 |
2.17 |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
|
|
0 |
| 4426-3 |
Spironolactone |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Spironolactone [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4426-3 |
|
|
|
|
Observation |
|
|
|
0 |
Spironolactone Dose |
|
|
|
Y |
|
Aldactone; Dose med or substance; DRUG DOSES; Novospiroton; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 44260-8 |
Thoughts that you would be better off dead, or of hurting yourself in some way in last 2W |
Find |
^Patient |
2W |
Ord |
Reported.PHQ |
|
ACTIVE |
Thoughts that you would be better off dead, or of hurting yourself in some way in last 2 weeks [Reported.PHQ] |
|
MIN |
DefinitionDescription |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
SURVEY.PHQ |
|
44260-8 |
|
Reported.PHQ |
|
|
Observation |
|
|
|
0 |
|
|
PHQ-9.9 |
Thoughts that you would be better off dead, or of hurting yourself in some way |
N |
|
14 days; 2 weeks; Finding; Findings; Mental health; MentalHealth; Ordinal; Past; Patient Health Questionnaire; Psych; Psychiatry; Ql; Qual; Qualitative; Screen; Survey; SURVEY.PHQ; You be better dead, or hurting yourself |
2.54 |
2.17 |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
|
|
0 |
| 44261-6 |
Patient health questionnaire 9 item total score |
Score |
^Patient |
Pt |
Qn |
Reported.PHQ |
|
ACTIVE |
Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] |
|
MIN |
DefinitionDescription |
|
|
score |
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
SURVEY.PHQ |
|
44261-6 |
|
Reported.PHQ |
|
|
Observation |
|
|
|
0 |
|
|
PHQ-9.9 |
|
N |
|
Mental health; MentalHealth; Patient Health Questionnaire; PHQ; PHQ 9; PHQ9; PHQ-9; PHQ-9 total score; Point in time; Psych; Psychiatry; QNT; Quan; Quant; Quantitative; Random; Scale; Survey; SURVEY.PHQ; Tot; Totl |
2.73 |
2.17 |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
{score} |
|
|
|
0 |
| 44262-4 |
PHQ-9 interpretation |
Imp |
^Patient |
Pt |
Ord |
Reported.PHQ |
|
DEPRECATED |
Deprecated PHQ-9 interpretation |
|
DEL |
DefinitionDescription |
|
|
|
|
Copyright �© Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute. |
|
|
|
|
SURVEY.PHQ |
|
44262-4 |
|
Reported.PHQ |
|
|
Observation |
|
|
|
0 |
|
|
|
|
N |
|
Impression; Impression/interpretation of study; Impressions; Interp; Interpret; Interpretation; Interpt; Intrp; Ordinal; Patient Health Questionnaire; PHQ9; Point in time; QL; Qual; Qualitative; Random; Screen; Survey; SURVEY.PHQ |
2.4 |
2.17 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 44263-2 |
Influenza virus A RNA |
ACnc |
XXX |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Influenza virus A RNA [Units/volume] (viral load) in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
28.1 |
|
|
|
|
|
MICRO |
|
44263-2 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
FLUAV RNA Spec NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Avian influenza; Bird flu; DNA NUCLEIC ACID PROBE; DNA probe; FLUA; FLUAV; FLUV; Fowl plague; ID; Infectious Disease; InfectiousDisease; Influ; Influenza A; Influenza A virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral load |
2.69 |
2.17 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 44264-0 |
Influenza virus A H5 RNA |
ACnc |
XXX |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Influenza virus A H5 RNA [Units/volume] (viral load) in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
28.1 |
|
|
|
|
|
MICRO |
|
44264-0 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
FLUAV H5 RNA Spec NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Avian influenza; Bird flu; DNA NUCLEIC ACID PROBE; DNA probe; FLUA; FLUAV; FLUAV H5; FLUV; Fowl plague; ID; Infectious Disease; InfectiousDisease; Influ; Influenza A; Influenza A virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral load |
2.69 |
2.17 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 44265-7 |
Influenza virus A H6 RNA |
ACnc |
XXX |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Influenza virus A H6 RNA [Units/volume] (viral load) in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
28.1 |
|
|
|
|
|
MICRO |
|
44265-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
FLUAV H6 RNA Spec NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Avian influenza; Bird flu; DNA NUCLEIC ACID PROBE; DNA probe; FLUA; FLUAV; FLUAV H6; FLUV; Fowl plague; ID; Infectious Disease; InfectiousDisease; Influ; Influenza A; Influenza A virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral load |
2.69 |
2.17 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 44266-5 |
Influenza virus A H7 RNA |
ACnc |
XXX |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Influenza virus A H7 RNA [Units/volume] (viral load) in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
28.1 |
|
|
|
|
|
MICRO |
|
44266-5 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
FLUAV H7 RNA Spec NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Avian influenza; Bird flu; DNA NUCLEIC ACID PROBE; DNA probe; FLUA; FLUAV; FLUAV H7; FLUV; Fowl plague; ID; Infectious Disease; InfectiousDisease; Influ; Influenza A; Influenza A virus; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Viral load |
2.69 |
2.17 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 44267-3 |
Avian paramyxovirus 1 RNA |
ACnc |
XXX |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Avian paramyxovirus 1 RNA [Units/volume] (viral load) in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
28.1 |
|
|
|
|
|
MICRO |
|
44267-3 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
APMV1 RNA Spec NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; APMV; APMV1; APMV-1; Arbitrary concentration; Avian paramyxovirus type 1; Avian pneumoencephalitis; Bird; DNA NUCLEIC ACID PROBE; DNA probe; Fowl; i; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; NDV; Newcastle disease; Nucleic acid sequence based analysis; Other; Paramyxo virus; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Vet; Veterinary; Viral load |
2.69 |
2.17 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 44268-1 |
Avian paramyxovirus 1.exotic RNA |
ACnc |
XXX |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Avian paramyxovirus 1.exotic RNA [Units/volume] (viral load) in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
28.1 |
|
|
|
|
|
MICRO |
|
44268-1 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
Exotic APMV1 RNA Spec NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; APMV; APMV1; APMV-1; Arbitrary concentration; Avian paramyxovirus type 1; Avian pneumoencephalitis; Bird; DNA NUCLEIC ACID PROBE; DNA probe; END; Exotic APMV1; Exotic Newcastle Disease; Fowl; i; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; NDV; Newcastle disease; Nucleic acid sequence based analysis; Other; Paramyxo virus; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; Unspecified; Vet; Veterinary; Viral load |
2.69 |
2.17 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 44269-9 |
Bacillus anthracis cell wall Ag |
PrThr |
XXX |
Pt |
Ord |
IF |
|
ACTIVE |
Bacillus anthracis cell wall Ag [Presence] in Specimen by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
Presumptive identification of B. anthracis cells by fluoroimmunoassay. No B. anthracis cells by fluoroimmunoassay |
|
|
|
|
|
MICRO |
|
44269-9 |
|
IF |
|
|
Both |
|
|
|
0 |
B anthracis cell wall Ag Spec Ql IF |
|
|
|
N |
|
ACIF; Anthrax; Anticomplement Immunofluorescence; Antigen; Antigens; B anthracis; B anthracis cell wall; Charbon; DFA; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Malignant carbuncle; Malignant pustule; Microbiology; Milzbrand; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; Splenic fever; Time Resolved Fluorescence; To be specified in another part of the message; TRF; Unspecified; Woolsorters disease |
2.69 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 4427-1 |
Stanozolol |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Stanozolol [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4427-1 |
|
|
|
|
Observation |
|
|
|
0 |
Stanozolol Dose |
|
|
|
Y |
|
Androstanazole; Dose med or substance; DRUG DOSES; Methylstanazole; Point in time; QNT; Quan; Quant; Quantitative; Random; Stromba; Strombaject; Winstrol |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
| 44270-7 |
Bacillus anthracis spore Ag |
PrThr |
XXX |
Pt |
Ord |
IF |
|
ACTIVE |
Bacillus anthracis spore Ag [Presence] in Specimen by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
Presumptive identification of B. anthracis spores by fluoroimmunoassay. No B. anthracis spores detected by fluoroimmunoassay |
|
|
|
|
|
MICRO |
|
44270-7 |
|
IF |
|
|
Both |
|
|
|
0 |
B anthracis spore Ag Spec Ql IF |
|
|
|
N |
|
ACIF; Anthrax; Anticomplement Immunofluorescence; Antigen; Antigens; B anthracis; B anthracis spore; Charbon; DFA; FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Malignant carbuncle; Malignant pustule; Microbiology; Milzbrand; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; Splenic fever; Time Resolved Fluorescence; To be specified in another part of the message; TRF; Unspecified; Woolsorters disease |
2.69 |
2.17 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 44271-5 |
Brucella sp Ag |
Prid |
XXX |
Pt |
Nom |
IF |
|
ACTIVE |
Brucella sp Ag [Identifier] in Specimen by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
Presumptive identification of Brucella spp. No Brucella abortus, melitensis, or suis detected |
|
|
|
|
|
MICRO |
|
44271-5 |
|
IF |
|
|
Both |
|
|
|
0 |
Brucella Ag Spec IF |
|
|
|
N |
|
ACIF; Anticomplement Immunofluorescence; Antigen; Antigens; Bruc; Brucellosis; DFA; FA; Fluorescent antibody; Fluoresent; ID; Identity or presence; IFA; Immune fluorescence; Immunoflour; Immunofluor; Immunofluorescence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Nominal; Other; Point in time; Random; Spec; species; spp; Time Resolved Fluorescence; To be specified in another part of the message; TRF; Unspecified |
2.69 |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
0 |
